Search

Displaying results 3361 - 3370 of 10000 in total
  1. Drug

    Sodium tartrate

    go.drugbank.com/drugs/DB13707
    ApprovedWithdrawn

    This compound is commonly used as an emulsifier in cheese/cheese spread products and is not to exceed 4% concentration, according to Health Canada regulations [L2594].

  2. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    It was granted accelerated approval by the FDA in May 2017 [A192807] for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. … [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in

  3. Drug

    Ibrutinib

    go.drugbank.com/drugs/DB09053
    ApprovedInvestigational

    April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. … [A32299] Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval;[L12228] however, in

  4. Drug

    Argatroban

    go.drugbank.com/drugs/DB00278
    ApprovedInvestigational

    Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban. … Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi.

  5. Drug

    Naloxegol

    go.drugbank.com/drugs/DB09049
    ApprovedInvestigational

    through the blood-brain barrier. … The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system

    Categories: Peripheral Opioid Receptor Antagonists
  6. Drug

    Oxamniquine

    go.drugbank.com/drugs/DB01096
    Approved

    Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. … (From Martidale, The Extra Pharmacopoeia, 31st ed, p121)

  7. Drug

    Capreomycin

    go.drugbank.com/drugs/DB00314
    ApprovedInvestigational

    Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus.

  8. Drug

    Tovorafenib

    go.drugbank.com/drugs/DB15266
    ApprovedInvestigational

    [A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. … [A263602] Tovorafenib inhibits BRAF and blocks dysregulated signalling pathways related to cancer cell growth and survival.[L50587]

  9. Drug

    Cevimeline

    go.drugbank.com/drugs/DB00185
    Approved

    It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome. … Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.

    Categories: Cholinergic Receptor Agonist
  10. Drug

    Flunarizine

    go.drugbank.com/drugs/DB04841
    ApprovedInvestigational

    It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.

    Synonyms: 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine